Can Biotech Sustain the Venture Capital Investment Surge?

In 2017, the biotech sector experienced over $9.3 billion in venture funding in 471 deals, including several mega-deals such as Unity Biotechnology and ADC Therapeutics. While 2017 was, by far, one of the best years for biotech venture funding since 2010, the question is can that momentum continue through 2018?

Read More

5 Big Biotech IPOs of 2016

This year has not exactly been the year of the IPO. In addition to fewer overall offerings, the total value of the IPO market is far less than last year. Nonetheless, certain industries are continuing to see a fair amount of activity, and biotech in particular has done relatively well. Here are some of the big biotech IPOs of 2016:

Read More

The Biggest Mergers & Acquisitions of 2016

This year, a lot of mergers and acquisitions (M&A) ended up falling apart. However, even though this year was not as strong as the prior year, there were still plenty of high value transactions. There continues to be consolidation among firms in technology, healthcare, life sciences, and communications, but plenty of other industries saw some fairly large deals as well. Here are some of the more noteworthy transactions that occurred:

Read More

Venture Capital Trends in Biotech

Last year, venture capital funding for the biotechnology sector reached record levels, which obviously caused the broader medical category to reach a new high as well. Even though many markets began to experience declines toward the end of last year and are continuing to witness these declines this year, it does not look like the same is true for biotechnology. Granted, there was a flurry of IPO activity in the early months of 2015 that likely will not repeat itself this year, but corporate venture capital and corporate equity investors appear poised to continue to bolster the surging biotech sphere. The following aspects of biotech seem particularly attractive to investors right now:

Read More

6 Ways Your Biotech Startup Can Make the Most of A Data Room

To be successful in the biotech industry you need a minimum of three things; an innovative technology, significant capital, and patience - a lot of it. If it was only that simple, right? As you know businesses in the biotech industry are regularly met with extreme regulation, and other enormous roadblocks along the way, which means that the cost of doing business is high. This results in most companies participating in continuous fundraising, innovation, and often a series of strategic partnerships. Not to mention extreme sensitivity around the company's intellectual property, and other critical corporate information.

 

So, when you are met with such significant obstacles while on the road to achieve great technological breakthroughs you absolutely need a tool that can help streamline and protect all of your efforts. That is where a secure virtual data room can lend a helping hand. Here is how:

Read More

Biotech IPOs Roaring Along: How a Virtual Data Room Can Help

Lately, there has been relatively slow IPO activity in virtually all sectors, except for one. Last year and so far this year, the health care sector, with biotechnology leading the way, has had the most IPOs, and it doesn’t look like it is about to slow down. For many companies, the IPO process can seem daunting because there are copious details to consider and numerous items to handle. However, it doesn’t have to be a mad dash to the finish or an overly stressful ordeal. Careful planning and diligent preparation will ensure a smooth and (at least somewhat) less stressful IPO. Here are some important ways that using a virtual data room can facilitate the process:

Read More

Why Biotech Startup Funding is on the Rise and Here to Stay

Biotech startup funding is better than you think, and funding growth could be here for the long term. No one can blame early stage biotech startups grumbling about the difficulties getting funded, especially when their challenges are contrasted with software startups.  Billion dollar valuations for software companies with no revenue have given way to deca billion dollar companies with no revenue.  Coupled with ongoing drumbeat of relentless cutting and restructuring R&  at almost all Big Pharma companies, it’s easy to wallow in a pessimistic swamp regarding early stage funding for life science startups, except for one thing:  Startup funding for Biotechs is blowing up.  Not only that, the long-term trend points to continued growth in early stage life science investment.  So what’s changed?

Read More

The Latest Biotech Trends

The increasing integration of science and technology is transforming the health care industry. Older technology continues to undergo striking enhancements, while new technology is constantly emerging, drastically changing the biotechnological sphere. These advancements have brought about a discernible shift in the approach to diagnosing and treating diseases, and innovative technology is at the forefront of this biomedical revolution.

Read More

Investment Banks are Targeted by Hackers-Why CFOs Should be Concerned

 

At the end of last summer, the WSJ blog commented on the number of financial institutions posting job ads for cyber security positions. Now that cyber security encompasses a broad range of issues and security breaches are disturbingly pervasive, it seems that investment banks are looking to hire tech-savvy information security personnel as a solution to protect their online systems. Which begs the question, is that in the best interest of the bank's clients?

Read More

Bio International 2014 Perspectives

 

Read More